A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).
Publication
, Conference
Tew, WP; Sill, M; McMeekin, DS; Secord, AA; Bonebrake, AJ; Schilder, J; Stuckey, A; Rice, L; Tewari, KS; Aghajanian, C
Published in: Journal of Clinical Oncology
May 20, 2014
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5546 / 5546
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Tew, W. P., Sill, M., McMeekin, D. S., Secord, A. A., Bonebrake, A. J., Schilder, J., … Aghajanian, C. (2014). A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). In Journal of Clinical Oncology (Vol. 32, pp. 5546–5546). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5546
Tew, William P., Michael Sill, D Scott McMeekin, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne Schilder, Ashley Stuckey, Laurel Rice, Krishnansu Sujata Tewari, and Carol Aghajanian. “A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).” In Journal of Clinical Oncology, 32:5546–5546. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5546.
Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, et al. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5546–5546.
Tew, William P., et al. “A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5546–5546. Crossref, doi:10.1200/jco.2014.32.15_suppl.5546.
Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, Stuckey A, Rice L, Tewari KS, Aghajanian C. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5546–5546.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5546 / 5546
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences